KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Enterprise Value (2016 - 2026)

West Pharmaceutical Services has reported Enterprise Value over the past 18 years, most recently at -$521.4 million for Q1 2026.

  • Quarterly Enterprise Value fell 29.0% to -$521.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$521.4 million through Mar 2026, down 29.0% year-over-year, with the annual reading at -$791.3 million for FY2025, 63.29% down from the prior year.
  • Enterprise Value was -$521.4 million for Q1 2026 at West Pharmaceutical Services, up from -$791.3 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$404.2 million in Q1 2025 and troughed at -$898.6 million in Q3 2023.
  • The 5-year median for Enterprise Value is -$667.7 million (2022), against an average of -$666.1 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 45.37% in 2024 and later plummeted 63.29% in 2025.
  • Tracing WST's Enterprise Value over 5 years: stood at -$894.3 million in 2022, then grew by 4.52% to -$853.9 million in 2023, then skyrocketed by 43.25% to -$484.6 million in 2024, then plummeted by 63.29% to -$791.3 million in 2025, then soared by 34.11% to -$521.4 million in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$521.4 million, -$791.3 million, and -$628.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.